Home › Focal Segmental Glomerulosclerosis › Minnesota
Focal Segmental Glomerulosclerosis clinical trials in Minnesota
5 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in Minnesota.
Cities in Minnesota
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- InterMed Consultants - Edina Clinic- Site Number : 8400019, Edina
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- University of Minnesota, Minneapolis
Recruiting
Up to age 21 · All sexes · Updated Aug 28, 2026 · NCT02235857Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- University of Minnesota, Masonic Children's Hospital, Minneapolis
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986SLIT ABS: Study on Patients With Autoimmune Podocytopathy
- Mayo Clinic, Rochester
Recruiting
Ages 0 to 99 · All sexes · Updated Apr 8, 2026 · NCT07516964A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 12 to 80 · All sexes · Updated Feb 3, 2026 · NCT05183646From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.